SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    G.F. Abu Zeinah, S.G. Al-Kindi, A.A. Hassan, A. Allam, Hyponatraemia in cancer: association with type of cancer and mortality, European Journal of Cancer Care, 2015, 24, 1
  2. 2
    Tsung-Hsing Hung, Chih-Wei Tseng, Kuo-Chih Tseng, Yu-Hsi Hsieh, Chih-Chun Tsai, Chen-Chi Tsai, Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients With Hepatic Encephalopathy, Medicine, 2014, 93, 14, e79

    CrossRef

  3. You have free access to this content3
    Hendrik Vilstrup, Piero Amodio, Jasmohan Bajaj, Juan Cordoba, Peter Ferenci, Kevin D. Mullen, Karin Weissenborn, Philip Wong, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 2014, 60, 2
  4. 4
    Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases, Journal of Hepatology, 2014, 61, 3, 642

    CrossRef

  5. 5
    Jonathan Merola, Noami Chaudhary, Meng Qian, Alexander Jow, Katherine Barboza, Hearns Charles, Lewis Teperman, Samuel Sigal, Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation, Journal of Clinical Medicine, 2014, 3, 2, 359

    CrossRef

  6. 6
    Guo Shen, Hainv Gao, Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review, Case Reports in Hepatology, 2014, 2014, 1

    CrossRef

  7. 7
    Joseph G. Verbalis, Steven R. Goldsmith, Arthur Greenberg, Cynthia Korzelius, Robert W. Schrier, Richard H. Sterns, Christopher J. Thompson, Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations, The American Journal of Medicine, 2013, 126, 10, S1

    CrossRef

  8. 8
    Gitte Dam, Susanne Keiding, Ole L. Munk, Peter Ott, Hendrik Vilstrup, Lasse K. Bak, Helle S. Waagepetersen, Arne Schousboe, Michael Sørensen, Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake, Hepatology, 2013, 57, 1
  9. 9
    Evangelos Kalaitzakis, Axel Josefsson, Maria Castedal, Pia Henfridsson, Maria Bengtsson, Bengt Andersson, Einar Björnsson, Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis, Scandinavian Journal of Gastroenterology, 2013, 48, 5, 577

    CrossRef

  10. 10
    Ewout J. Hoorn, Robert Zietse, Hyponatremia and Mortality: Moving Beyond Associations, American Journal of Kidney Diseases, 2013, 62, 1, 139

    CrossRef

  11. 11
    I. Umbro, F. Tinti, F. Fiacco, A. Zavatto, P. Piselli, V. Di Natale, S. Lai, A. Vitarelli, S. Ginanni Corradini, M. Rossi, L. Poli, P.B. Berloco, A.P. Mitterhofer, Resistive Index and MELD-Na: Nephrologic Monitoring in Cirrhotic Patients Awaiting Liver Transplantation, Transplantation Proceedings, 2013, 45, 7, 2676

    CrossRef

  12. 12
    Hugh Watson, Peter Jepsen, Florence Wong, Pere Ginès, Juan Córdoba, Hendrik Vilstrup, Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development, Metabolic Brain Disease, 2013, 28, 2, 301

    CrossRef

  13. 13
    T. H. HUNG, C. J. LAY, C. M. CHANG, J .J. TSAI, C. C. TSAI, C. C. TSAI, The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy, Epidemiology and Infection, 2013, 141, 12, 2671

    CrossRef

  14. 14
    Mauro Bernardi, Paolo Caraceni, Roberta J. Navickis, Mahlon M. Wilkes, Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials, Hepatology, 2012, 55, 4
  15. 15
    Elsa Solà, Hugh Watson, Isabel Graupera, Fanny Turón, Rogelio Barreto, Ezequiel Rodríguez, Marco Pavesi, Vicente Arroyo, Mónica Guevara, Pere Ginès, Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema, Journal of Hepatology, 2012, 57, 6, 1199

    CrossRef

  16. 16
    Oliviero Riggio, Silvia Nardelli, Federica Moscucci, Chiara Pasquale, Lorenzo Ridola, Manuela Merli, Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt, Clinics in Liver Disease, 2012, 16, 1, 133

    CrossRef

  17. 17
    Robert W. Schrier, Shailendra Sharma, Dmitry Shchekochikhin, Hyponatraemia: more than just a marker of disease severity?, Nature Reviews Nephrology, 2012, 9, 1, 37

    CrossRef

  18. 18
    Paul Gaglio, Kwaku Marfo, Joseph Chiodo, Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan, Digestive Diseases and Sciences, 2012, 57, 11, 2774

    CrossRef

  19. You have free access to this content19
    E. Dahl, L. L. Gluud, N. Kimer, A. Krag, Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia, Alimentary Pharmacology & Therapeutics, 2012, 36, 7
  20. 20
    Gilles Pomier-Layrargues, Louis Bouchard, Michel Lafortune, Julien Bissonnette, Dave Guérette, Pierre Perreault, The Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Portal Hypertension: Current Status, International Journal of Hepatology, 2012, 2012, 1

    CrossRef

  21. 21
    Andrés Cárdenas, Pere Ginès, Acute-on-chronic liver failure: the kidneys, Current Opinion in Critical Care, 2011, 17, 2, 184

    CrossRef

  22. 22
    Won Hyeok Choe, The use of vaptan in hyponatremic patients with liver cirrhosis, The Korean Journal of Hepatology, 2011, 17, 4, 335

    CrossRef